
The company reported that Acuvue Oasys Max 1-Day and Oasys 1-Day outperformed the other 5 daily disposable lenses evaluated in a recent study, among other Johnson & Johnson data highlights at AAOpt 2026.
A presbyopia-correcting eyedrop recently received FDA acceptance of its investigational new drug (IND) application
Rhett Schiffman, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.